Agenus Inc. Stock News

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsa...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus' anti-PD-1 a...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatel...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus' anti-PD-1 antibody, in patient...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curativ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026. Agenus plans to host a webcast later in August to discuss its corporate priorities, including the acceleration of the botensilimab and balstilimab (BOT+B...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in M...

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an addi...